<DOC>
	<DOC>NCT00926731</DOC>
	<brief_summary>A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.</brief_summary>
	<brief_title>Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Newly diagnosed patient. Provision of written informed consent. De Novo (primary) or Secondary AML. Not eligible for intensive induction chemotherapy because of medical, social or psychological reasons. Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL). Patients with blast crisis of chronic myeloid leukaemia. Persistent, chronic, clinically significant toxicities from any prior anti cancer therapy greater than CTCAE Grade 1 (except alopecia).</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Acute Myeloid Leukaemia (AML)</keyword>
</DOC>